MediGene Significantly Increased Revenues in the First Nine Months
2007
* Significant increase in total revenues to 18.6 million EUR
compared to
13.4 million EUR (9M-2006)
* Loss on EBIT-level increased to -23.2 million EUR compared
to
-10.9 million EUR (9M 2006)
* Cash and cash equivalents on September 30, 2007: 54.6
million EUR (31.12.2006: 52.5
million EUR)
* Forecast for the year adjusted
Martinsried/Munich, November 9, 2007. In the first nine months and in
the third quarter 2007, the biotech company MediGene AG (Frankfurt,
Prime Standard: MDG) achieved a significant increase in revenues. At
the same time there has been a considerable rise in net loss for the
period, due to the company's increase in research and development
expenses.
Total revenues increased by 39 % to 18.6 million EUR in the first
nine months of 2007, compared to 13.4 million EUR in last year's
reporting period. The increase in the third quarter was particularly
significant: total revenues rose by 64 % to 6.2 million EUR (Q3 2006:
3.7 million EUR). Revenues were generated mainly from the
commercialization of EligardÒ in Europe, whereas a 4.1 million EUR
milestone payment made by MediGene's partner Bradley Pharmaceuticals
Inc. contributed to the nine-months result in 2006.
The loss before interest and tax (EBIT) in the first nine months
increased by 113 % to
-23.2 million EUR (9M 2006: -10.9 million EUR). In the third quarter
2007, the loss on EBIT basis increased by 30 % to -7.5 million EUR
(Q3 2006: -5.8 million EUR). This increase is mainly a consequence of
the consolidation of MediGene Ltd. since September 2006, and an
extension of the clincial and preclinical development programs.
Consolidated Income Statement (abbreviated)
in T¤ Q3 2007 Q3 2006 Change 9M 2007 9M 2006 Change
Total revenues 6,151 3,743 64 % 18,605 13,356 39 %
Cost of sales -4,541 -2,843 60 % -14,181 -6,430 121 %
Gross profit 1,610 900 79 % 4,424 6,926 -36 %
Selling,
general, and -2,052 -1,640 25 % -6,836 -4,588 49 %
administrative
expenses
Research and
development -7,068 -5,016 41 % -20,788 -13,250 57 %
expenses
Operating -7,510 -5,756 30 -23,200 -10,912 113 %
result (EBIT) %
Result before -7,371 -5,444 35 -22,280 -9,983 123 %
income tax %
(EBT)
Net loss for -7,249 -5,444 33 % -20,041 -9,983 101 %
the period
Compared to the closing date December 31, 2006, the cash position
increased by 4 % to 54.6 million EUR as a result of financing
activities. Cash flow from operating activities in the same period
was -26.2 million EUR.
Major events since the beginning of 2007:
* Approval procedure in Europe for the six-months dosage of
Eligard® completed, product launched in Germany
* Marketing authorization application for the Polyphenon® E
Ointment for the treatment
of genital warts submitted to the regulatory authorities in
Germany, Austria, and Spain
* Decision about European marketing authorization for Oracea®
postponed to 2008
* Initiation of a further phase II trial of EndoTAG®-1 in the
indication triple receptor-negative breast cancer
* Clinical phase IIa trial of RhuDex® for the treatment of
rheumatoid arthritis initiated
Outlook and forecast 2007:
For the ongoing financial year 2007, MediGene expects total revenues
of 24 million ¤. In contrast to the previous years, the revenues will
be generated mainly by product sales arising from the
commercialization of Eligard®. In addition, revenues include payments
received under the terms of research cooperations as well as public
grants. The original revenues forecast for 2007, i.e. revenues of 35
million ¤, included initial product sales of Oracea®, the approval
for which is now expected in 2008, as well as additional proceeds
from new cooperation agreements which MediGene no longer expects for
this year.
However, MediGene expects a lower loss in financial year 2007 than
originally planned. Compared to the original forecast of 35 million ¤
EBIT-based loss, the company now expects a loss of approximately 32
million ¤. Although research and development activities were
significantly extended compared to last year, operational costs did
not increase to the extent originally expected.
Due to lower operational costs than expected, and as a consequence of
successful capital increases, year-end cash reserves are expected to
be approximately 45 million ¤ (original forecast: 25 million ¤).
MediGene assumes that the commercialization of the six-months depot
formulation will give additional impetus to Eligard® sales. Moreover
US market launch of the Polyphenon® E Ointment by MediGene's partner
Bradley Pharmaceuticals is expected by the end of the year. MediGene
expects the decision about the marketing authorization application
for Oracea® in the first six months of 2008.
In the field of research and development, MediGene expects the
conclusion of the clinical part oft the phase IIa trial of the drug
candidate RhuDex® for the treatment of rheumatoid arthritis. The data
from this trial are expected now in the first half of 2008. The
results from the first phase II trial of EndoTAG®-1 are scheduled for
publication in the first six months of 2008.
MediGene's detailed 9-Months Report is accessible on the Internet at:
http://www.medigene.de/englisch/quartalsberichte.php?jahr=2007
This press release contains forward-looking statements that involve
risks and uncertainties. The forward-looking statements contained
herein represent the judgment of MediGene as of the date of this
release. These forward-looking statements are no guarantees for
future performance, and the forward-looking events discussed in this
press release may not occur. MediGene disclaims any intent or
obligation to update any of these forward-looking statements.
EndoTAGTM-1 and the MediGeneTM Logo are trademarks of MediGene AG,
Eligard® is a trademark of Atrix Laboratories/Sanofi-Aventis,
Polyphenon E® is a trademark of Mitsui Norin, Oracea® is a trademark
of CollaGenex, Inc., RhuDex® is a trademark of MediGene Ltd.
- ends -
MediGene AG is a publicly quoted (Frankfurt: Prime Standard: MDG)
biotechnology company located in Martinsried/Munich, Germany, with
subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first
German biotech company with a drug on the market. Another drug
obtained marketing authorization for the USA and a further drug is
currently undergoing the European approval procedures. Furthermore
MediGene has several drug candidates for the treatment of various
types of cancer and autoimmune diseases in clinical development, and
possesses innovative platform technologies for drug development.
Contact MediGene AG:
Email:
investor@medigene.com
Fax: ++49 - 89 - 85 65 - 2920
Julia Hofmann/Dr. Georg Dönges, Public
Relations Tel.: ++49 - 89 - 85 65 - 3317
Dr. Michael Nettersheim, Investor
Relations Tel.: ++49 - 89 - 85 65
- 2946
--- End of Message ---
MediGene AG
Lochhamer Strasse 11 Martinsried / München Germany
WKN:
502090; ISIN: DE0005020903 ; Index: Prime All Share, CDAX, TECH All
Share, HDAX, MIDCAP, TecDAX;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Bayerische Börse München,
Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Niedersächsische Börse zu Hannover,
Geregelter Markt in Frankfurter Wertpapierbörse;